Skip to main content
. 2020 Dec;17(12):1576–1582. doi: 10.1513/AnnalsATS.202005-521OC

Table 2.

Patients with PAH or CTEPH who were recognized to have COVID-19

Patients with PAH/CTEPH with recognized COVID-19 50
Hospitalizations among patients with recognized COVID-19 15
Intensive care unit stays among patients with recognized COVID-19 11
Deaths among patients with recognized COVID-19 6
Total number of reported patients with PAH/CTEPH followed by centers 16,979
Cumulative incidence of recognized COVID-19 among patients with PAH/CTEPH (per 1,000 patients)
 Overall cumulative incidence of recognized COVID-19 2.9 (95% CI, 2.2–3.9)
 Cumulative incidence in patients from states with a low COVID-19 incidence 1.4 (95% CI, 0.8–2.4)
 Cumulative incidence in patients from states with a high COVID-19 incidence 4.6 (95% CI, 3.4–6.4)
U.S. cumulative incidence of COVID-19 (per 1,000 inhabitants)* 2.4
Centers with patients with PAH/CTEPH recognized to have COVID-19, n (%)
 No patients 37 (64)
 One patient 8 (14)
 Two patients 6 (10)
 Three patients 5 (9)
 Four or more patients 2 (3)
Among centers with at least one patient with COVID-19, centers that used a potential targeted therapy, n (%)
 Hydroxychloroquine 6 (29)
 Chloroquine 2 (9)
 Azithromycin 3 (14)
 Remdesivir 2 (9)
 Steroids 3 (14)
 Vitamin C 3 (14)
 Convalescent sera 1 (5)
 Tocilizumab (or other interleukin therapy) 2 (9)
 iNO 1 (5)
 Centers who tried none of these therapies 13 (62)

Definition of abbreviations: CDC = Centers for Disease Control and Prevention; CI = confidence interval; COVID-19 = coronavirus disease; CTEPH = chronic thromboembolic pulmonary hypertension; iNO = inhaled nitric oxide; PAH = pulmonary arterial hypertension.